Magis Mandapathil

Magis Mandapathil practices at Hanover SurgiCenter in Hanover, Pennsylvania.

Magis Mandapathil's NPI, 1982084158, was assigned on June 3, 2015. Magis Mandapathil holds Pennsylvania license MD483328.

Magis Mandapathil's primary practice is Hanover SurgiCenter, at 50 Fame Ave. Suite 130, Hanover, PA 17331. The practice phone is (717) 633-1600. Magis Mandapathil also practices at Hanover Surgicenter, L.L.C., 250 Fame Ave, Hanover, PA 17331.

Magis Mandapathil's primary practice is Hanover SurgiCenter in Hanover, Pennsylvania. Magis Mandapathil is also affiliated with UPMC Hanover. The medical group on file is UPMC Pinnacle Health Systems. Dmand AI also links Magis Mandapathil to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Magis Mandapathil practices, 6 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Magis Mandapathil's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dmand AI has Magis Mandapathil's licenses on file in 2 states: Pennsylvania and New York.

CMS data shows 869 Medicare services from Magis Mandapathil across 9 procedure codes in 2024, for 335 Medicare patients. Medicare paid $56,446 for them. Every service was in an office.

CMS counts 335 Medicare patients who saw Magis Mandapathil in 2024. The largest group is 65 to 74, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.21, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Magis Mandapathil's median patient age at 66, with 60% women.

In 2024, Magis Mandapathil wrote 630 Medicare Part D claims for 232 patients. 98% of them were for generic drugs. CMS names the drug for 550 of them, across 13 drugs with 11 or more claims each, at $10,035 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Magis Mandapathil for performance year 2024, reported as part of a group. Magis Mandapathil accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 3 general payments to Magis Mandapathil from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 93% of the total. Inspire Medical Systems, Inc. paid the most, $146.